Background and purpose: Although inorganic arsenite (As III ) is toxic in humans, it has recently emerged as an effective chemotherapeutic agent for acute promyelocytic leukemia (APL). In humans and most animals, As III is enzymatically methylated in the liver to weakly toxic dimethylarsinic acid (DMAs V ) that is a major pentavalent methylarsenic metabolite. Recent reports have indicated that trivalent methylarsenicals are produced through methylation of As III and participate in arsenic poisoning. Trivalent methylarsenicals may be generated as arsenical-glutathione conjugates, such as dimethylarsinous glutathione (DMAs III G), during the methylation process. However, less information is available on the cytotoxicity of DMAs III G. Experimental approach: We synthesized and purified DMAs III G using high performance TLC (HPTLC) methods and measured its cytotoxicity in rat liver cell line (TRL 1215 cells). Key results: DMAs III G was highly cytotoxic in TRL 1215 cells with a LC 50 of 160 nM. We also found that DMAs III G molecule itself was not transported efficiently into the cells and was not cytotoxic; however it readily became strongly cytotoxic by dissociating into trivalent dimethylarsenicals and glutathione (GSH). The addition of GSH in micromolar physiological concentrations prevented the breakdown of DMAs III G, and the DMAs III G-induced cytotoxicity. Physiological concentrations of normal human serum (HS), human serum albumin (HSA), and human red blood cells (HRBC) also reduced both the cytotoxicity and cellular arsenic uptake induced by exposure to DMAs III G.
Introduction
Arsenic is a metalloid that is widely distributed in the environment in inorganic trivalent (inorganic arsenite; As III ) or pentavalent (inorganic arsenate; As V ) forms (Morton and Dunnette, 1994) , and its high toxicity is well known. Epidemiological studies have provided clear evidence that inorganic arsenicals are human carcinogens (NRC, 1999) ; however, As III has recently emerged as an outstanding chemotherapeutic agent with remarkable efficacy for certain human cancers such as acute promyelocytic leukemia (APL) Shen et al., 1997) . In humans and numerous experimental animals, As III is enzymatically methylated in the liver to organic arsenicals such as monomethylarsonic acid (MMAs V ) and dimethylarsinic acid (DMAs V ) (Yamauchi and Yamamura, 1979; Buchet et al., 1980) . MMAs V and DMAs V are the major organic pentavalent arsenic metabolites found in human urine after exposure to inorganic arsenicals. It is believed that the methylation of inorganic arsenicals results in a reduction in general toxicity, as indicated by increases in the values for LD 50 and the in vitro lethal concentration in 50% of a population (LC 50 ) (Sakurai et al., 1998 (Sakurai et al., , 2002 . However, recent studies have increasingly suggested that the methylation of inorganic arsenicals is not a universal detoxification metabolic reaction. Wang et al. (2004) reported that trivalent dimethylarsenicals were found in the urine collected from APL patients undergoing As III treatment. The synthetic trivalent dimethylarsenicals, such as iododimethylarsine (DMAs III I), were more cytotoxic in vitro than inorganic arsenicals and pentavalent methylarsenicals (Styblo et al., 2000; Mass et al., 2001) . Recent evidence has suggested that trivalent methylarsenicals may be generated as arsenical-glutathione (GSH) conjugates, such as dimethylarsinous glutathione (DMAs III G), in the human body (Hayakawa et al., 2005) ;
however, due to its instability, little information is available on the cytotoxicity of DMAs III G (Styblo et al., 2000; Hayakawa et al., 2005) .
In this study, we synthesized and purified DMAs III G using a high-performance TLC (HPTLC) method and observed the cytotoxicity of the synthesized DMAs III G using rat liver cells.
The liver is a major site of arsenic methylation. We found that DMAs III G itself was not transported efficiently into the cells and was not cytotoxic; however, it readily became highly cytotoxic in a neutral solution by a chemical conversion to the trivalent dimethylarsenite ion (DMAs III þ ) and/or dimethylarsinous acid (DMAs III OH). The addition of GSH in micromolar physiological concentrations inhibited this chemical change and prevented the cytotoxicity of trivalent dimethylarsenicals.
Methods

Cell culture
The TRL 1215 cell line is a rat epithelial liver cell line originally derived from the liver of 10-day-old Fisher F344 rats (Idoine et al., 1976) . TRL 1215 cells were cultured in William's E medium (Sigma) supplemented with 10% heatinactivated fetal bovine serum (FBS), 2 mM glutamine, 100 U ml À1 penicillin G and 100 mg ml À1 streptomycin under a humidified atmosphere of 5% CO 2 /95% air at 371C.
Arsenic analysis
Preparation of arsenic samples. Arsenicals in samples from HPTLC or cellular arsenicals in TRL 1215 cells exposed to arsenicals were analyzed by atomic absorption spectrophotometry (AAS), HPLC-inductively coupled argon plasma (ICP) MS (HPLC-ICP MS) or fast atom bombardment MS (FAB-MS). TRL 1215 cells which were grown in flat-bottomed 75-cm 2 tissue culture flask to confluence (8 Â 10 7 cells/flask) and incubated with arsenicals were isolated by trypsinization and resuspended in 1 ml of ice-cold 0.25 M sucrose solution that included 50 mM Tris-HCl (pH 7.5), 10 mM potassium chloride, 5 mM magnesium chloride, 1 mM dithiothreitol and 1 mM phenylmethanesulfonyl fluoride, and sonicated on ice using MICROSON ultrasonic homogenizer (Model XL2007, Misonix Inc., Farmingdale, NY, USA). The degree of cell rupture was checked by phase-contrast microscopy and 95% cell rupture was sufficient. The suspension of ruptured cells was centrifuged at 2000 g for 10 min, and divided into the supernatant (cytoplasm) and the pellet (cell membrane and nucleus). The pellet was suspended again in 1 ml of ice-cold 0.25 M sucrose solution, placed on ice-cold 1 M sucrose and centrifuged at 1500 g for 10 min. The cell membrane at the 0.25 M sucrose/1 M sucrose interface was collected with a pipette, rinsed with 0.25 M sucrose solution and resuspended in 1 ml of distilled water. Three milliliters of nitric acid and 1 ml of sulfuric acid were then added to the solutions of cytoplasm or cell membrane, heated at 2401C until sulfur trioxide was visible, and the digested solutions were neutralized with ammonium hydroxide.
AAS. The aqueous solutions containing arsenicals prepared from HPTLC samples or TRL 1215 cells exposed to arsenicals were made in a volume of 8 ml with distilled water, and 1 ml of hydrochloric acid, 0.5 ml of 20% ascorbic acid and 0.5 ml of 20% potassium iodide were added to the solutions. Arsenic in the solutions was analyzed by hydride generation coupled with AAS (Ohta et al., 2004; Sakurai et al., 2005) using SpestraAA-220 (Varian Australia Pty Ltd, Mulgrave, Victoria, Australia). The cellular arsenic content was expressed as nanograms of arsenicals per milligram of cellular protein, as determined by BCA protein assay (Pierce Co., Rockford, IL, USA), or expressed as nM calculated using total cell numbers and estimated cell density (2.4 Â 10 À9 cm 3 /cell) as measured using a hemacytometer counting chamber (Mizoguchi and Hara, 1996; Sakurai et al., 2005) .
HPLC-ICP MS. Arsenicals extracted from TLC were also analyzed by HPLC-ICP MS and FAB-MS. For HPLC-ICP MS analysis (Shraim et al., 2001; Hayakawa et al., 2005; Sakurai et al., 2005) , 10 ml of a sample solution was applied to a reversed-phase C18 column (Inertsil ODS; GL Sciences Inc., Tokyo, Japan) connected to an L-6200 Inteligent pump (Hitachi Ltd, Ibaraki, Japan) with a mobile phase of 5 mM tetrabutylammonium hydroxide, 3 mM malonic acid and 5% methanol at flow rate of 1 ml min
À1
. The outlet of the HPLC system was coupled directly to the inlet of the ICP MS (ELAN 6000, Perkin-Elmer Co., Norwalk, CT, USA), and signals at m/z 75 and 77 (corresponding to arsenicals and ArCl, respectively) were monitored. Tri Chemical Co. (Yamanashi, Japan). These purchased arsenicals were recrystallized twice, and their purities were 499.9% as determined by gas chromatography/mass spectrometry (GC/MS) (Sakurai et al., 2004a) . Endotoxin contamination of these arsenicals was not detected (o0.0000003%, wt/wt) using the endotoxin-specific limulus test (Seikagaku Co., Tokyo, Japan). GSH, oxidized form of (Scott et al., 1993; Kala et al., 2000) , and separated by HPTLC method (see details in Results section). HPTLC was performed on 0.1 mm precoated silica gel HPTLC plates (Merck KgaA, Darmstadt, Germany) with a developing solvent of ethyl acetate:acetic acid:water (3:2:1), and iodine vapor was used for the visual detection of DMAs III G (Sakurai et al., 2002) . Separated DMAs III G was collected from the HPTLC plate with silica gel and stored at À851C. DMAs III G was extracted by ice-cold distilled water before experimental use and centrifuged at 20 000 g for 5 min at 41C to remove silica gel. Supernatants were then filtered through 0.20 mm filters and used as an aqueous solution of DMAs III G.
Results
Preparation of DMAs III G by HPTLC
It has been reported that GSH nonenzymatically reduces DMAs V to DMAs III G in water (Scott et al., 1993; Kala et al., 2000) . In order to determine the likelihood of DMAs III G production, 10 mM DMAs V was incubated with or without 10-50 mM GSH in distilled water for 1 h at 371C. After incubation, these mixtures were applied to an HPTLC plate and developed using ethyl acetate:acetic acid:water (3:2:1). Separated compounds were detected with iodine vapor. As shown in Figure Figure 3c , when cells were exposed to 200 nM DMAs III G for 48 h at 371C, the cellular arsenic content increased quickly from 10 min and reached a peak at 12 h exposure, when cell death was still low (Figure 3b) 
DMAs III G is an unstable chemical
The purified DMAs III G extracted from HPTLC was preincubated in water for 1-48 h at 371C, and its cytotoxicity was then observed. As shown in Figure 4a , preincubation reduced the cytotoxicity of DMAs III G in a time-dependent manner.
Preincubation for 1 h at 371C or more significantly reduced, and a 48 h preincubation completely abolished, the cytotoxicity induced by DMAs III G. As shown in Figure 4b , DMAs III G-induced cytotoxicity was significantly reduced by preincubation in water at a temperature greater than 41C; however, the cytotoxicity was retained after a preincubation at À851C. Figure 5 shows that preincubation of DMAs III G in water for 24 or 48 h at 371C also reduced its cellular uptake into TRL 1215 cells. Most arsenicals accumulated in the cytoplasm of the cells. As shown in Figure 5b , a DMAs III G HPTLC spot also disappeared after preincubation in water at 371C in a time-dependent manner. However, the addition of GSH prevented this and a visible DMAs III G HPTLC spot was retained in a GSH concentration-dependent manner even after a 48 h preincubation at 371C (lanes 12-15; similar results are also shown in Figure 8 , lanes 7 and 8).
Exogenous GSH prevented DMAs III G-induced cytotoxicity by reducing cellular uptake of DMAs III G Figure 6 shows that exogenous GSH prevented DMAs III Ginduced cytotoxicity in TRL 1215 cells, either at millimolar (Figure 6b ). Similar effects were observed with other thiol reagents, such as cysteine and N-acetyl-L-cysteine (NAC) (Figure 6a ), but was not observed with GSSG (data not shown). Figure 7 shows that exogenous GSH also inhibited the uptake of DMAs (Figures 7a and b) . In contrast, exogenous GSH did not affect the cellular uptake of other arsenic compounds, such as As III and DMAs V , at any concentration (Figure 7a ).
Serum, serum albumin and red blood cells prevented DMAs III Ginduced cytotoxicity by reducing the cellular uptake of DMAs III G 
Other signals originating from the glycerol matrix were observed at m/z 369.
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Discussion
Recently, an inorganic arsenical -As III -was found to be effective in inducing complete remission in patients with APL Shen et al., 1997) . Multiple As III injections (10 mg day
À1
) for at least 28 consecutive days are required to induce complete remission (Shen et al., 1997) . Methylated arsenicals are formed from inorganic arsenicals by enzymatic methylation (Hindmarsh and McCurdy, 1986) and accumulate in the human body during As III treatment as a chemotherapeutic agent (Wang et al., 2004; Fukai et al., 2006) . Arsenic intoxication also occurs widely through the consumption of contaminated well water or foods containing inorganic arsenicals (Morton and Dunnette, 1994; NRC, 1999); therefore, the accumulation of the metabolites of inorganic arsenicals is likely to occur. It was recently reported that toxic trivalent dimethylarsenic compounds might be produced through the methylation of inorganic arsenicals (Wang et al., 2004) , and that the cytotoxicity of a synthetic trivalent dimethylarsenic compound -DMAs III I -was higher than that of inorganic arsenicals (Styblo et al., 2000; Mass et al., 2001 III G was preincubated in distilled water for 0-48 h at À85, 4, 22 or 371C. TRL 1215 cells were exposed to 500 nM of these preincubated DMAs III G for 48 h at 371C, and cellular viability was then assessed by the AlamarBlue assay. All results are expressed as the arithmetic mean7s.e.m. of three separate experiments each performed in triplicate (n ¼ 9). *Po0.001, in comparison to the cells exposed to the same concentrations of DMAs III G without preincubation, **Po0.01, ***Po0.05.
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DMAs
III G was formed in vitro ( Figure 9 ). In this study, we confirmed the formation of the DMAs-GSH conjugate DMAs III G during the incubation of 10 mM DMAs V with 30 mM GSH for 1 h at 371C using HPLC-ICP MS and FAB-MS analysis. We readily purified this chemical by an HPTLC method and observed its in vitro cytotoxicity using rat liver TRL 1215 cells. Purified DMAs III G was much more cytotoxic than either As III or DMAs v ; and its LC 50 value was 160 nM.
However, this action of purified DMAs III G was readily reduced by preincubation in water at temperatures greater than 41C. The high cellular arsenic uptake of DMAs III G and a visible DMAs III G HPTLC spot were also greatly reduced by preincubation. Under our experimental conditions, only GSH and/or GSH-conjugated chemicals could be visually detected by iodine vapor on an HPTLC plate; however, a DMAs V spot could not be detected. Thus, the GSH molecule might readily be removed from DMAs III G during the preincubation period. The released DMAs III þ might subsequently be converted in water to DMAs III OH and finally be oxidized to the weakly toxic pentavalent dimethylarsenic compound DMAs V (Figure 9 ).
The submicromolar LC 50 values of DMAs III G determined in this study are very important in the elucidation of the actual role of the metabolic methylation of arsenicals in the human body, because other major human arsenic metabolites, including inorganic arsenicals, do not show cytotoxicity in mammalian cells at the submicromolar level (Sakurai et al., 1998 (Sakurai et al., , 2002 . Additionally, it has been reported that the mean blood concentration of total arsenical was in the submicromolar range in relapsed APL patients, in whom complete remission had been induced by As III treatment (Fukai et al., 2006) ; similar levels were found in the blood of patients with chronic arsenic poisoning in Inner Mongolia, China and northeastern Taiwan who continued to drink well water containing high concentrations of inorganic arsenicals (Pi et al., 2000; Wu et al., 2003) . Interestingly, exogenous thiol agents, such as GSH, cysteine and NAC, greatly decreased both the cytotoxicity and cellular arsenic contents induced by DMAs III G exposure. The addition of GSH inhibited the preincubation-induced disappearance of the visible DMAs III G spot on HPTLC plates. It is generally 
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believed that the large GSH molecule is not transported efficiently into cells (De Flora et al., 2001) . Therefore, these thiol agents may maintain the molecular form of DMAs III G so that DMAs III G itself cannot subsequently be transported into cells. The significant cytotoxicity induced by DMAs III G could be the result of the dissociation of the conjugate into trivalent dimethylarsenic compounds and GSH, the former probably becoming DMAs III þ and/or DMAs III OH, before being transported into cells (Thompson, 1993; Dopp et al., 2004 Dopp et al., , 2005 (Figure 9 ). We showed in this study that a GSSG Figure 9 Putative chemical reactions of dimethylarsenic compounds with GSH.
Cytotoxicity of dimethylarsinous glutathione T Sakurai et al spot appeared when purified DMAs III G was applied and developed again on a new HPTLC plate, indicating that the GSH molecule readily dissociates from DMAs III G and is converted to oxidized GSH. The plasma GSH concentrations remain at micromolar levels in healthy humans (Donner et al., 1998; Kokcam and Naziroglu, 1999) , and we showed in this study that exogenous GSH at micromolar levels prevented submicromolar DMAs III G-induced cytotoxicity. In addition, the physiological concentrations of normal HS, HSA and HRBC significantly reduced both the cytotoxicity and cellular arsenic contents induced by DMAs III G exposure. . GSH may be a key molecule in preventing chronic arsenic toxicity. Clearly, if GSH levels are reduced, inorganic arsenicals are more toxic and induce complete necrosis in mammalian cells (Sakurai et al., 1998 (Sakurai et al., , 2002 . GSH depletion causes an essentially minor, nontoxic, human monomethylarsenic metabolite -MMAs V -to become toxic (Sakurai et al., 2004a (Sakurai et al., , 2005 . DMAs V appears unable to induce apoptosis after GSH depletion (Sakurai et al., 1998 (Sakurai et al., , 2002 (Sakurai et al., , 2004b ) that allows the survival of damaged abnormal cells. Furthermore, the strongly toxic DMAs III G may exert its cytotoxicity by dissociating into DMAs III þ and GS À and by being transported into cells after depletion of blood GSH levels. GSH may be also a cofactor in the enzymatic methylation of inorganic arsenicals in humans (Zakharyan et al., 2001; Hayakawa et al., 2005) . These findings suggest that GSH depletion may trigger the disruption of the arsenic detoxifying system and induce various arsenic toxicities in humans. In fact, reduced nonprotein sulfhydryl levels in peripheral blood, often seen as an indicator of GSH levels, were observed in chronic arsenic poisoning patients in Inner Mongolia, China (Pi et al., 2000) . Further research will be required in order to determine the role of metabolic methylation and GSH in arsenic toxicity in APL patients who are injected with As III as a chemotherapeutic agent and/or in chronic arsenic poisoning in those who regularly ingest inorganic arsenic-contaminated well water.
